L. Jeremy Stigall's Insider Trades & SAST Disclosures
L. Jeremy Stigall's most recent trade in ClearPoint Neuro Inc was a trade of 15,497 Restricted Stock Units done . Disclosure was reported to the exchange on March 12, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern L. Jeremy Stigall.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| ClearPoint Neuro Inc | Jeremy L. Stigall | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2025 | 15,497 | 61,990 | - | - | Restricted Stock Units | |
| ClearPoint Neuro Inc | Jeremy L. Stigall | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2025 | 15,497 | 79,853 (0%) | 0% | - | Common Stock | |
| ClearPoint Neuro Inc | Jeremy L. Stigall | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.18 per share. | 12 Mar 2025 | 5,545 | 74,308 (0%) | 0% | 13.2 | 73,083 | Common Stock |
| ClearPoint Neuro Inc | Jeremy L. Stigall | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2025 | 8,292 | 67,323 (0%) | 0% | - | Common Stock | |
| ClearPoint Neuro Inc | Jeremy L. Stigall | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2025 | 8,292 | 8,291 | - | - | Restricted Stock Units | |
| ClearPoint Neuro Inc | Jeremy L. Stigall | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.70 per share. | 11 Mar 2025 | 2,967 | 64,356 (0%) | 0% | 12.7 | 37,681 | Common Stock |
| ClearPoint Neuro Inc | Jeremy L. Stigall | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2025 | 17,777 | 17,778 | - | - | Restricted Stock Units | |
| ClearPoint Neuro Inc | Jeremy L. Stigall | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2025 | 17,777 | 65,392 (0%) | 0% | - | Common Stock | |
| ClearPoint Neuro Inc | Jeremy L. Stigall | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.19 per share. | 06 Mar 2025 | 6,361 | 59,031 (0%) | 0% | 13.2 | 83,902 | Common Stock |
| ClearPoint Neuro Inc | Jeremy L. Stigall | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 44,280 | 44,280 | - | - | Restricted Stock Units | |
| ClearPoint Neuro Inc | Jeremy L. Stigall | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.72 per share. | 22 Feb 2025 | 908 | 47,615 (0%) | 0% | 16.7 | 15,182 | Common Stock |
| ClearPoint Neuro Inc | Jeremy L. Stigall | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 4.53 per share. | 31 Dec 2024 | 251 | 48,523 (0%) | 0% | 4.5 | 1,137 | Common Stock |
| ClearPoint Neuro Inc | Jeremy L. Stigall | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.26 per share. | 20 Aug 2024 | 420 | 48,272 (0%) | 0% | 11.3 | 4,729 | Common Stock |
| ClearPoint Neuro Inc | Jeremy L. Stigall | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 4.58 per share. | 28 Jun 2024 | 3,500 | 48,692 (0%) | 0% | 4.6 | 16,030 | Common Stock |
| ClearPoint Neuro Inc | Jeremy L. Stigall | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.74 per share. | 10 Jun 2024 | 2,502 | 45,192 (0%) | 0% | 5.7 | 14,361 | Common Stock |
| ClearPoint Neuro Inc | Jeremy L. Stigall | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2024 | 77,487 | 77,487 | - | - | Restricted Stock Units | |
| ClearPoint Neuro Inc | Jeremy L. Stigall | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2024 | 16,583 | 16,583 | - | - | Restricted Stock Units | |
| ClearPoint Neuro Inc | Jeremy L. Stigall | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2024 | 8,889 | 50,874 (0%) | 0% | 0 | Common Stock | |
| ClearPoint Neuro Inc | Jeremy L. Stigall | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2024 | 8,889 | 35,555 | - | - | Restricted Stock Units | |
| ClearPoint Neuro Inc | Jeremy L. Stigall | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.24 per share. | 06 Mar 2024 | 3,180 | 47,694 (0%) | 0% | 6.2 | 19,843 | Common Stock |
| ClearPoint Neuro Inc | L. Jeremy Stigall | GM, Biologics & Drug Delivery | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.49 per share. | 22 Feb 2024 | 1,039 | 41,985 (0%) | 0% | 7.5 | 7,782 | Common Stock |
| ClearPoint Neuro Inc | L. Jeremy Stigall | GM, Biologics & Drug Delivery | Grant, award, or other acquisition of securities at price $ 5.77 per share. | 29 Dec 2023 | 378 | 43,024 (0%) | 0% | 5.8 | 2,181 | Common Stock |
| ClearPoint Neuro Inc | Jeremy L. Stigall | GM, Biologics & Drug Delivery | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.53 per share. | 06 Jul 2023 | 1,730 | 42,646 (0%) | 0% | 6.5 | 11,297 | Common Stock |
| ClearPoint Neuro Inc | Jeremy L. Stigall | GM, Biologics & Drug Delivery | Grant, award, or other acquisition of securities at price $ 6.15 per share. | 30 Jun 2023 | 2,682 | 44,376 (0%) | 0% | 6.1 | 16,494 | Common Stock |
| ClearPoint Neuro Inc | Jeremy L. Stigall | GM, Biologics & Drug Delivery | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.91 per share. | 10 Jun 2023 | 1,212 | 41,694 (0%) | 0% | 6.9 | 8,375 | Common Stock |
| ClearPoint Neuro Inc | Jeremy L. Stigall | GM, Biologics & Drug Delivery | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 44,444 | 44,444 | - | - | Restricted Stock Units | |
| ClearPoint Neuro Inc | Jeremy L. Stigall | GM, Biologics & Drug Delivery | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 14,814 | 14,814 | - | - | Stock Option (Right to Buy) | |
| ClearPoint Neuro Inc | Jeremy L. Stigall | GM, Biologics & Drug Delivery | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.55 per share. | 22 Feb 2023 | 514 | 42,906 (0%) | 0% | 8.6 | 4,395 | Common Stock |
| ClearPoint Neuro Inc | Jeremy L. Stigall | GM, Biologics & Drug Delivery | Other type of transaction at price $ 7.20 per share. | 31 Dec 2022 | 728 | 43,420 (0%) | 0% | 7.2 | 5,242 | Common Stock |
| ClearPoint Neuro Inc | Jeremy L. Stigall | GM, Biologics & Drug Delivery | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.24 per share. | 20 Aug 2022 | 203 | 42,692 (0%) | 0% | 13.2 | 2,688 | Common Stock |
| ClearPoint Neuro Inc | Jeremy L. Stigall | GM, Biologics & Drug Delivery | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.87 per share. | 06 Jul 2022 | 1,685 | 41,526 (0%) | 0% | 13.9 | 23,371 | Common Stock |
| ClearPoint Neuro Inc | Jeremy L. Stigall | GM, Biologics & Drug Delivery | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 17,528 | 43,211 (0%) | 0% | 0 | Common Stock | |
| ClearPoint Neuro Inc | Jeremy L. Stigall | GM, Biologics & Drug Delivery | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 11,685 | 11,685 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges